Compare Cytokinetics Inc (CYTK) vs H2O America (HTO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs H2O America — how do they compare? Cytokinetics Inc trades at $76.73 (market cap $10.63B), while H2O America trades at $62.73 (market cap $2.61B). The key difference: Cytokinetics Inc is far larger — about 4.1× H2O America's market cap, and H2O America pays a 2.83% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | HTO | |
|---|---|---|
Market Cap | $10.63B | $2.61B |
Sector | Technology | Technology |
52-Week High | $87.26 | $65.43 |
52-Week Low | $34.31 | $44.44 |
Enterprise Value | $10.74B | $4.40B |
Dividend Yield | — | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.
The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.
HTO trades at $62.39, up 1.87% today, with a bullish technical signal from moving averages and support near $61. Recent earnings show Q2 2026 adjusted EPS of $0.72 beating expectations, while Q4 2025 missed. Revenue grew to $829 million in 2026, with a net margin of 12.9%. The company announced a $0.44 dividend payable September 1, 2026, and faces execution risks from acquisitions like Quadvest, which diluted shares.
The stock offers upside to the $69.50 consensus price target, supported by strong analyst buy ratings (83%) and institutional accumulation. Risks include acquisition integration challenges and EPS pressure from equity issuance. Fundamentals remain solid with steady profitability, but investors should monitor debt levels and dividend sustainability amid expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About H2O America
H2O America is a utility company that provides essential water and wastewater services, primarily in the United States. The company operates a network of regulated water and wastewater systems, focusing on responsible resource management and high-quality service delivery. HTO aims to expand its operational footprint through acquisitions and internal growth, serving residential, commercial, and industrial customers.
Read more on HTO →
